Amobarbital

Phase 3Small molecule

TTongji Hospital

Amobarbital is one of 45 small molecule programs targeting Osteoarthritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoarthritisTerminated

Adverse ReactionNot yet recruiting

OsteoarthritisPreclinical

Terminated

Adverse ReactionPhase 3

Not yet recruiting

Competition

Competitive Landscape

143 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Amobarbital

TTongji Hospital

Phase 3

1 2

Toradol

Roche

Preclinical

1 3

Cataflam

Bayer Aspirin

Enbrel

2 6

Glucophage

EMD Serono

Preclinical

1 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 8

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adverse Reaction1 trial

Effect of Amobarbital Sodium Combined With Low-dose Propofol on Hemodynamics During Induction and Perioperative Adverse Reactions

Not yet recruiting·TTongji Hospital·Phase 4·NCT06385756·96 enrolled

Osteoarthritis1 trial

Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA

Terminated·JJ L Marsh·Preclinical·NCT04589611·5 enrolled

Cardiopulmonary Bypass1 trial

The Effect of Amobarbital on Myocardial Protection and Prognosis in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass

Completed·TTongji Hospital·Preclinical·NCT06757868·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Amobarbital. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amobarbital compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amobarbital. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tongji Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTongji Hospital

Amobarbital

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adverse Reaction1 trial

Osteoarthritis1 trial

Cardiopulmonary Bypass1 trial

References

Drug Info

Quick Facts

Related News